NasdaqGS:GILDBiotechs
Gilead (GILD) Wins Key Europe Backing For Trodelvy In Triple Negative Breast Cancer
The European Medicines Agency’s CHMP has issued a positive opinion for Trodelvy plus Keytruda in first line treatment of PD-L1 positive metastatic triple negative breast cancer.
The recommendation is based on Phase 3 data showing a substantial reduction in disease progression or death versus standard care.
A European Commission decision will follow, which could expand Trodelvy’s approved uses in Europe if approval is granted.
Gilead Sciences (NasdaqGS: GILD) is drawing attention after the...